02 · Clinical Findings
A new obesity trial puts tolerability beside the weight-loss number
Not the GLP-1 pathway at all. This one works through leptin, the hormone that tells you that you are full.
In a mid-stage study, an investigational amylin medicine was associated with up to 10.7% average weight loss at 42 weeks, while nausea was the most common gastrointestinal side effect. The study also reported that most participants reached their target maintenance dose.
The finding matters because tolerability can shape whether an early treatment result is usable outside a trial. It is still company-presented mid-stage evidence, not a head-to-head answer about which medicine is best or who will tolerate it.
Phase 3 trials need to confirm both the weight-loss signal and the side-effect profile over longer follow-up. The clinical question is not only how much weight changed, but whether the result can hold in a broader population.
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
Combining two diabetes drug classes is not automatically a bigger clinical benefit
At the highest dose, retatrutide cut 21% of body weight in people with type 2 diabetes
Tirzepatide kept nearly 99% of prediabetes patients diabetes-free over three years
Continue reading · Clinical FindingsPeptide News / Clinical FindingsStaying on a GLP-1 medicine is a clinical question, not just a prescribing numberFierce Pharma · Jun 7, 2026 · scroll to read